Mavyret and Reyataz

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using atazanavir together with glecaprevir is not recommended. Combining these medications may increase the risk of liver problems related to high concentrations of the bile pigment bilirubin. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. You should seek immediate medical attention if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

CONTRAINDICATED: Coadministration with atazanavir plus ritonavir may significantly increase the plasma concentrations of glecaprevir. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1-mediated hepatic uptake of glecaprevir by atazanavir and ritonavir. Inhibition of P-glycoprotein-mediated intestinal efflux and CYP450 3A4-mediated metabolism of glecaprevir may also contribute. When glecaprevir-pibrentasvir 300 mg-120 mg once daily was administered with atazanavir 300 mg plus ritonavir 100 mg once daily to 12 study subjects, glecaprevir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) increased by approximately 4.1-, 6.5- and 14.3-fold, respectively. Pibrentasvir pharmacokinetics were modestly affected, with Cmax, AUC and Cmin increasing by approximately 1.3-, 1.6- and 2.3-fold, respectively. High plasma levels of glecaprevir may increase the risk of adverse effects such as alanine aminotransferase (ALT) and bilirubin elevations. In addition, both glecaprevir and atazanavir inhibit OATP1B1 and uridine diphosphate glucuronosyl transferase (UGT) 1A1, which may impact transport and metabolism of bilirubin, including both direct and indirect. Additive effects may occur and increase the risk of hyperbilirubinemia.

MANAGEMENT: Concomitant use of glecaprevir with atazanavir is considered contraindicated.

Mavyret

Generic Name: glecaprevir / pibrentasvir

Brand name: Mavyret

Synonyms: n.a.

What is Mavyret?

Reyataz

Generic Name: atazanavir

Brand name: Reyataz

Synonyms: n.a.

What is Reyataz?